FitForFrance: Study to Assess the Pain, Satisfaction, and Quality of Life of Patients With FITBONE® Lengthening Nail
Study Details
Study Description
Brief Summary
This study is a prospective observational non-interventional multi-centre cohort study of patients, 12 years or older, initiating a lower limb lengthening procedure with FITBONE and who have a length discrepancy of 30mm or more between the limbs.
The following parameters will be assessed for up to 24 months.
-
Pain using the Visual Analog Scale (VAS), Patient Global Assessment (PGA) and Clinical Observer Global Assessment (COGA)
-
Patient satisfaction using the Patient Global Impression of change (PGI-C) scale
-
QoL using the 36-Item Short Form Survey/Paediatric Quality of Life Inventory (SF-36/PedsQL)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The study period is 24 months post-surgery. Each patient's demographic data, medical history, any relevant concomitant medication, physical examination, range of motion data will be recorded using a standardized case record form after informed consent is provided and the healthcare provider completes a physical examination regarding the patient's conditions and record determination as to whether FITBONE is recommended. The decision to treat, observe, and to include in this observation study is at the discretion of the healthcare provider. This is an observational study and therefore, the participating healthcare provider will manage patients according to the usual clinical practice.
Surgery will be performed according to the standard surgical procedure described previously. Study of Investigational Product(s). Five to ten days after the lengthening nail placement, the lengthening mechanism is operated by transmitting energy necessary for the lengthening from the outside. This period is referred to as the distraction period. The rhythm of lengthening and strict protocol for an individual patient, indicating the daily lengths of lengthening to be applied, are decided by the healthcare provider taking into account all influencing factors. Therefore, the end of the distraction period, bone healing, implant removal, and 6 months post-implant removal may differ by individual. In the event the distraction period is extended by the healthcare provider, the new distraction period will determine the end of the distraction time point. All patients will be followed until the end of the scheduled study period regardless of any change in their treatment or other conditions.
Six visits are planned:
-
Surgery (baseline)
-
End of the distraction phase
-
End of bone healing
-
Implant removal
-
6-month post-removal
-
24-month post-surgery The satisfaction will be assessed at implant removal, 6 months post implant removal, and 24 months post-surgery.
The QoL will be assessed at baseline, at 6 months post implant removal, and 24 months post-surgery.
Pain will be assessed at all timepoints. Measurement of pain at the end of the distraction phase, the patient will be requested to report the pain experienced in the past week, at the moment, and during or immediately after the distraction period. At other time points, pain for only at the moment will be captured.
Range of motion (ROM) will be measured at the end of bone healing, and at the 24 months post-surgery.
Lengthening achieved will be measured at the end of bone healing. Any incidence of adverse events will be recorded at any point during the 24-month follow-up period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients Patients aged ≥12 years with congenital or acquired lower limb discrepancy, greater than 30mm |
Device: FITBONE® Lengthening Nail
The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.
After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation.
|
Outcome Measures
Primary Outcome Measures
- Pain by Visual Analog Scale (VAS) [from pre-operative to 24 months follow-up]
Pain will be measured by the Pain by Visual Analog Scale (VAS), performed by the patient, through the Patient Global Evaluation Assessment and by the physician (Clinical Observer Global Assessment). The VAS for pain ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain.
- Patient satisfaction [from implant removal date to 24 months follow-up]
A dedicated patients satisfaction questionnaire has been developed with key opinion leaders (KOLs) and expert groups on the limb leg discrepancy treatment. The satisfaction questionnaire is made of 5 questions, for each question the patient have to reply using the Patient Global Impression of change ranging from 1 to 7, with 1 representing "Very much improved" to 7 being "Very much worse".
- Assessing patient Quality of Life (QoL) difference before and after treatment using Short Form 36 Health Survey (SF-36) for adult patients and PedsQL (Pediatric Quality of Life Inventory) Generic Core Scale for children patients. [from pre-operative to 24 months follow-up]
The Quality of Life (QoL) will be measured by the Short Form 36 Health Survey (SF-36) or PedsQL (Pediatric Quality of Life Inventory) Generic Core Scale, depending on the patient's age at enrolment: SF-36 for adults and PedsQl for children. The assumption is that on average the QoL will be at least maintained between the baseline (pre-surgery) assessment and follow-up. Short Form 36 Health Survey has two components: Physical Component Summary (PCS) Minimum 0, Maximum 100; Mental Component Summary (MCS) Minimum 0, Maximum 100. Higher scores on both the Physical and Mental Component Summary scales indicate a better outcome, reflecting better health-related quality of life. The PedsQL Generic Core Scales are scored on a scale of 0 to 100, with higher scores indicating better health-related quality of life and 0 represents the worst health-related quality of life.
Secondary Outcome Measures
- Effectiveness of FITBONE by limb lengthening [up to bone healing, approximately 6 months]
The lengthening goal is considered 'achieved' when, at the end of bone healing, the limb length is within 5 mm of the lengthening objective defined by the investigator when using FITBONE.
- Incidence of product and treatment-related adverse events and device deficiencies assessed by the investigators [from surgery to 24 months follow-up]
The clinical safety of Fitbone will be measured Collecting and characterizing the complications (expressed as adverse events and device deficiencies) associated with FITBONE that will be assessed by the investigators.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients aged ≥12 years old, with congenital or acquired lower limb discrepancy greater than 30mm, undergoing femoral or tibia bone lengthening with FITBONE
-
Patients with a regular indication for a surgical intervention with FITBONE
-
The patient (or his/her legally acceptable representative) is capable of understanding the content of the Informed Consent Form (ICF)
-
The informed consent form is correctly obtained
Exclusion Criteria:
-
Patients with a medical condition that is contraindicated according to the FITBONE instruction for use
-
Patients with any conditions that, in the Investigator's opinion, may interfere with the study execution, including those likely to be lost to follow-up
-
Patients who are unable to participate due to safety reasons
-
Patients who already have or require the application of in-situ concomitant devices that cannot be safely removed (except for permitted concomitant devices)
-
Patients participating in another clinical trial or has taken part in any clinical study in the last 3 months from the enrolment period
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Orthofix s.r.l.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OCI_2301